Research progress on the relationship between obstructive sleep apnea hypopnea syndrome and metabolic syndrome_West China Medical Journal

Authors：

ZHU Liangdong ¹ , LIU Hongling ² , ZHAO Dan ³ ,  YE Xianwe ³

1. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan 418000, P. R. China;
2. Department of Respiratory and Critical Care Medicine, Guiqian International General Hospital, Guiyang, Guizhou 550002, P. R. China;
3. Department of Respiratory and Critical Care Medicine, Guizhou Provincial People’s Hospital, Guiyang, Guizhou 550002, P. R. China;

Corresponding author：

YE Xianwe, Email: yxw1205@163.com

Keywords：

Obstructive sleep apnea hypopnea syndrome; metabolic syndrome; hypertension

DOI：

10.7507/1002-0179.202004229

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, more and more studies have shown that obstructive sleep apnea hypopnea syndrome (OSAHS) and metabolic syndrome are closely related and interact with each other, while hypertension, abnormal glucose metabolism, lipid metabolism disorders and obesity, as the main components of metabolic syndrome, have been further studied. Continuous positive airway pressure is currently the main treatment for OSAHS. This review focuses on the association between OSAHS and hypertension, glucose metabolism abnormalities, lipid metabolism disorders, obesity and the effects of treatment with positive airway pressure, aiming to provide a theoretical basis for the pathogenesis and treatment of OSAHS complicated with metabolic syndrome.

Citation： ZHU Liangdong, LIU Hongling, ZHAO Dan, YE Xianwe. Research progress on the relationship between obstructive sleep apnea hypopnea syndrome and metabolic syndrome. West China Medical Journal, 2022, 37(1): 116-119. doi: 10.7507/1002-0179.202004229 Copy

1.	Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med, 2017, 13(3): 479-504.
2.	McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol, 2018, 36(1): 14-20.
3.	Masa JF, Mokhlesi B, Benítez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet, 2019, 393(10182): 1721-1732.
4.	Oscullo G, Torres G, Campos-Rodriguez F, et al. Resistant/refractory hypertension and sleep apnoea: current knowledge and future challenges. J Clin Med, 2019, 8(11): 1872.
5.	Kim J, Lee SK, Yoon DW, et al. Concurrent presence of obstructive sleep apnea and elevated homocysteine levels exacerbate the development of hypertension: a Koges six-year follow-up study. Sci Rep, 2018, 8(1): 2665.
6.	Zhou Y, Ding YL, Zhang JL, et al. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother, 2018, 97: 1397-1408.
7.	Koszegi S, Molnar A, Lenart L, et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J Physiol, 2018, 597(1): 193-209.
8.	Zaheer S, Taquechel K, Brown JM, et al. A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes. J Renin Angiotensin Aldosterone Syst, 2018, 19(1): 1470320317754178.
9.	Campos J, Ernst G, Blanco M, et al. Acute response to 7-day therapy with CPAP in patients with moderate to severe obstructive sleep apnea and cardiac arrhytmia. Sleep Sci, 2018, 11(1): 49-53.
10.	Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hypertension: an update. Hypertension, 2014, 63(2): 203-209.
11.	杨世宏, 马磊, 李凯, 等. 国内人群中OSAHS与2型糖尿病相关性的Meta分析. 临床耳鼻咽喉头颈外科杂志, 2016, 30(16): 1297-1301, 1307.
12.	Murphy AM, Thomas A, Crinion SJ, et al. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Eur Respir J, 2017, 49(4): 1601731.
13.	Plíhalová A, Westlake K, Polák J. Obstructive sleep apnoea and type 2 diabetes mellitus. Vnitr Lek, 2016, 62(Suppl 4): S79-S84.
14.	Kritikou I, Basta M, Vgontzas AN, et al. Sleep apnoea and the hypothalamic-pituitary-adrenal axis in men and women: effects of continuous positive airway pressure. Eur Respir J, 2016, 47(2): 531-540.
15.	Anusree SS, Sindhu G, Preetha Rani MR, et al. Insulin resistance in 3T3-L1 adipocytes by TNF-α is improved by punicic acid through upregulation of insulin signalling pathway and endocrine function, and downregulation of proinflammatory cytokines. Biochimie, 2018, 146: 79-86.
16.	Rehman K, Akash MSH, Liaqat A, et al. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr, 2017, 27(3): 229-236.
17.	Gündüz C, Basoglu OK, Hedner J, et al. Obstructive sleep apnoea independently predicts lipid levels: data from the European sleep apnea database. Respirology, 2018, 23(12): 1180-1189.
18.	Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes, 2010, 17(2): 161-165.
19.	Perry JC, D’Almeida V, Souza FG, et al. Consequences of subchronic and chronic exposure to intermittent hypoxia and sleep deprivation on cardiovascular risk factors in rats. Respir Physiol Neurobiol, 2007, 156(3): 250-258.
20.	杨立新, 唐旋, 周宁, 等. 北京版蒙特利尔认知评估量表在成人OSAHS认知功能评估中的应用及可靠性验证. 临床耳鼻咽喉头颈外科杂志, 2018, 32(1): 58-64.
21.	Brito FA, Pedrosa W, Maluf CB, et al. Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: is it time to change?. Atherosclerosis, 2018, 274: 243-250.
22.	Nadeem R, Singh M, Nida M, et al. Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med, 2014, 10(12): 1295-1302.
23.	Hamilton GS, Joosten SA. Obstructive sleep apnoea and obesity. Aust Fam Physician, 2017, 46(7): 460-463.
24.	Spörndly-Nees S, Igelström H, Lindberg E, et al. Facilitators and barriers for eating behaviour changes in obstructive sleep apnoea and obesity - a qualitative content analysis. Disabil Rehabil, 2014, 36(1): 74-81.
25.	Todea DA, Postolache P, Herescu AC, et al. Obesity and obstructive sleep apnea in acromegalic patients. Chest, 2013, 144(4): 1000A.
26.	Drager LF, Brunoni AR, Jenner R, et al. Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials. Thorax, 2015, 70(3): 258-264.

1. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med, 2017, 13(3): 479-504.
2. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol, 2018, 36(1): 14-20.
3. Masa JF, Mokhlesi B, Benítez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet, 2019, 393(10182): 1721-1732.
4. Oscullo G, Torres G, Campos-Rodriguez F, et al. Resistant/refractory hypertension and sleep apnoea: current knowledge and future challenges. J Clin Med, 2019, 8(11): 1872.
5. Kim J, Lee SK, Yoon DW, et al. Concurrent presence of obstructive sleep apnea and elevated homocysteine levels exacerbate the development of hypertension: a Koges six-year follow-up study. Sci Rep, 2018, 8(1): 2665.
6. Zhou Y, Ding YL, Zhang JL, et al. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother, 2018, 97: 1397-1408.
7. Koszegi S, Molnar A, Lenart L, et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J Physiol, 2018, 597(1): 193-209.
8. Zaheer S, Taquechel K, Brown JM, et al. A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes. J Renin Angiotensin Aldosterone Syst, 2018, 19(1): 1470320317754178.
9. Campos J, Ernst G, Blanco M, et al. Acute response to 7-day therapy with CPAP in patients with moderate to severe obstructive sleep apnea and cardiac arrhytmia. Sleep Sci, 2018, 11(1): 49-53.
10. Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hypertension: an update. Hypertension, 2014, 63(2): 203-209.
11. 杨世宏, 马磊, 李凯, 等. 国内人群中OSAHS与2型糖尿病相关性的Meta分析. 临床耳鼻咽喉头颈外科杂志, 2016, 30(16): 1297-1301, 1307.
12. Murphy AM, Thomas A, Crinion SJ, et al. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Eur Respir J, 2017, 49(4): 1601731.
13. Plíhalová A, Westlake K, Polák J. Obstructive sleep apnoea and type 2 diabetes mellitus. Vnitr Lek, 2016, 62(Suppl 4): S79-S84.
14. Kritikou I, Basta M, Vgontzas AN, et al. Sleep apnoea and the hypothalamic-pituitary-adrenal axis in men and women: effects of continuous positive airway pressure. Eur Respir J, 2016, 47(2): 531-540.
15. Anusree SS, Sindhu G, Preetha Rani MR, et al. Insulin resistance in 3T3-L1 adipocytes by TNF-α is improved by punicic acid through upregulation of insulin signalling pathway and endocrine function, and downregulation of proinflammatory cytokines. Biochimie, 2018, 146: 79-86.
16. Rehman K, Akash MSH, Liaqat A, et al. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr, 2017, 27(3): 229-236.
17. Gündüz C, Basoglu OK, Hedner J, et al. Obstructive sleep apnoea independently predicts lipid levels: data from the European sleep apnea database. Respirology, 2018, 23(12): 1180-1189.
18. Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes, 2010, 17(2): 161-165.
19. Perry JC, D’Almeida V, Souza FG, et al. Consequences of subchronic and chronic exposure to intermittent hypoxia and sleep deprivation on cardiovascular risk factors in rats. Respir Physiol Neurobiol, 2007, 156(3): 250-258.
20. 杨立新, 唐旋, 周宁, 等. 北京版蒙特利尔认知评估量表在成人OSAHS认知功能评估中的应用及可靠性验证. 临床耳鼻咽喉头颈外科杂志, 2018, 32(1): 58-64.
21. Brito FA, Pedrosa W, Maluf CB, et al. Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: is it time to change?. Atherosclerosis, 2018, 274: 243-250.
22. Nadeem R, Singh M, Nida M, et al. Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med, 2014, 10(12): 1295-1302.
23. Hamilton GS, Joosten SA. Obstructive sleep apnoea and obesity. Aust Fam Physician, 2017, 46(7): 460-463.
24. Spörndly-Nees S, Igelström H, Lindberg E, et al. Facilitators and barriers for eating behaviour changes in obstructive sleep apnoea and obesity - a qualitative content analysis. Disabil Rehabil, 2014, 36(1): 74-81.
25. Todea DA, Postolache P, Herescu AC, et al. Obesity and obstructive sleep apnea in acromegalic patients. Chest, 2013, 144(4): 1000A.
26. Drager LF, Brunoni AR, Jenner R, et al. Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials. Thorax, 2015, 70(3): 258-264.

West China Medical Journal

Research progress on the relationship between obstructive sleep apnea hypopnea syndrome and metabolic syndrome

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content